We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
- Authors
Fenaux, Pierre; Mufti, Ghulam J; Hellström-Lindberg, Eva; Santini, Valeria; Gattermann, Norbert; Germing, Ulrich; Sanz, Guillermo; List, Alan F; Gore, Steven; Seymour, John F; Dombret, Hervé; Backstrom, Jay; Zimmerman, Linda; McKenzie, David; Beach, C L; Silverman, Lewis R
- Abstract
In a phase III randomized trial, azacitidine significantly prolonged overall survival (OS) compared with conventional care regimens (CCRs) in patients with intermediate-2- and high-risk myelodysplastic syndromes. Approximately one third of these patients were classified as having acute myeloid leukemia (AML) under current WHO criteria. This analysis compared the effects of azacitidine versus CCR on OS in this subgroup.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 4, p562
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.23.8329